Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892039 | 0.91 | PTPN1 (0.58) | PTPN1PTPN2 | |
| SCHEMBL5188294 | 0.87 | PTPN1 (0.75) | PTPN1PTPN2 | |
| SCHEMBL5165546 | 0.85 | PTPN1 (0.65) | PTPN1PTPN2 | |
| SCHEMBL5166021 | 0.83 | PTPN1 (0.65) | PTPN1PTPN2 | |
| SCHEMBL7598745 | 0.79 | PTPN1 (0.49) | PTPN1PTPN2 | |
| SCHEMBL5892036 | 0.78 | PTPN1 (0.60) | PTPN1PTPN2 | |
| SCHEMBL5165550 | 0.78 | TAS2R14 (0.57) | — | |
| SCHEMBL5165954 | 0.75 | PTPN1 (0.53) | PTPN1PTPN2 | |
| SCHEMBL5166028 | 0.75 | TAS2R14 (0.48) | — | |
| SCHEMBL7189540 | 0.74 | PTPN1 (0.47) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | PTPN1 2/4885PTPN2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.